FDA calls for additional Ph III study for Basilea’s ceftobiprole

FDA calls for additional Ph III study for Basilea’s ceftobiprole


Swiss drugmaker Basilea Pharmaceutica saw its shares drop as much as 12% yesterday, after it revealed…

Antibiotics and Infectious diseasesBacteriaBasilea PharmaceuticaceftobiproleHealth Medical PharmaHealth Medical PharmaisavuconazoleMedicinePharmaceuticalRegulationTreatment of pneumoniaUSA

Astellas amends license deal for isavuconazole with Basilea


Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

Astellas’ antifungal study reports positive results


Astellas Pharma has announced positive topline data from the Phase III invasive aspergillosis study (SECURE)…

Asia-PacificAstellas PharmaBasilea PharmaceuticaDermatologicalsisavuconazolePharmaceuticalResearch

Basilea updates on isavuconazole development


Switzerland-based Basilea Pharmaceutica Ltd. (SIX: BSLN) provided an update today (July 17) on the Phase…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaisavuconazolePharmaceuticalResearch

Edison analysts' take on Basilea outlook


The protracted development of antibiotic ceftobiprole has left Swiss biotech firm Basilea Pharmaceutica…

Antibiotics and Infectious diseasesBasilea PharmaceuticaBiotechnologyceftobiproleFinancialisavuconazoleOncologyResearchToctino

GlaxoSmithKline gets global rights to Basilea's Toctino


UK pharma giant GlaxoSmithKline (LSE: GSK) says that its dermatology-focussed subsidiary Stiefel has…

Basilea PharmaceuticaceftobiproleDermatologicalsGlaxoSmithKlineisavuconazoleLicensingPharmaceuticalResearchStiefelToctino

Back to top